IP Library Granted Patent US 9,771,316
Granted Patent B2
US 9,771,316 · App. 14/761,897 · Granted Sep 26, 2017

Phenoxyalkylamine compound

Inventors: Yoshikatsu Kanai (Suita, JP); Shushi Nagamori (Suita, JP); Yoshihiko Kitaura (Nara, JP); Masahiro Neya (Kobe, JP); Naohiro Matsushita (Kobe, JP)
Assignees: Osaka University; KNC Laboratories Co., Ltd.
C07C217/48C07C211/09C07C217/04C07C217/72C07C255/37C07C255/54C07C271/16C07C271/20C07C317/22C07C317/28C07C323/20C07C323/25C07D209/48C07D213/68C07D215/22C07D215/233C07D215/26C07D263/32C07D277/28C07D295/08C07D307/52C07D333/20C07D401/12C07D403/12C07D405/04C07D405/06C07D409/04C07D409/06C07D413/04C07D413/06C07D417/04C07D417/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,771,316
App. No.
14/761,897
Granted
Sep 26, 2017
Kind
B2
Abstract

The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.

Claims (37)

1. A compound represented by the formula (I):

wherein

Ring A is an optionally substituted cyclic group,

Ring B is an optionally substituted cyclic group,

R 1 and R 2 are each independently a hydrogen atom, an optionally substituted alkyl group or an optionally substituted cycloalkyl group,

X is O, S, S(O), or S(O) 2 , and

n is an integer of 4 to 6,

or a salt thereof.

2. The compound or salt of claim 1 , wherein Ring A is a C 6-14 aryl group, an aromatic heterocyclic group or a non-aromatic heterocyclic group, each optionally substituted.

3. The compound or salt of claim 1 , wherein Ring A is optionally substituted phenyl.

4. The compound or salt of claim 1 , wherein Ring B is an optionally substituted aromatic group.

5. The compound or salt of claim 1 , wherein Ring B is phenyl or thienyl, each optionally substituted.

6. The compound or salt of claim 1 , wherein R 1 and R 2 are each independently a hydrogen atom or a C 1-6 alkyl group.

7. The compound or salt of claim 1 , wherein R 1 and R 2 are each independently a hydrogen atom or a C 1-3 alkyl group.

8. The compound or salt of claim 1 , wherein n is 4 or 5.

9. The compound or salt of claim 1 , wherein n is 4.

10. The compound or salt of claim 1 , wherein X is O.

11. A pharmaceutical composition comprising the compound or salt of claim 1 , and a pharmaceutically acceptable carrier.

12. A LAT-1 inhibitor comprising the compound or salt of claim 1 .

13. A method of treating cancer selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, breast cancer, brain tumor, stomach cancer, liver cancer, esophageal cancer, head and neck cancer, and tongue cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the formula (I):

wherein

Ring A is optionally substituted phenyl,

Ring B is optionally substituted phenyl,

R 1 and R 2 are each independently a hydrogen atom, an optionally substituted alkyl group or an optionally substituted cycloalkyl group,

X is O, and

n is an integer of 4 to 6,

or a salt thereof.

14. The method of claim 13 , wherein the cancer is pancreatic cancer or lung cancer.

15. A compound represented by the formula (12):

wherein

Ring A is an optionally substituted cyclic group,

Ring B is an optionally substituted cyclic group,

R 1 is a hydrogen atom, an optionally substituted alkyl group or an optionally substituted cycloalkyl group,

X 1 is O, S or NR 3 wherein R 3 is a hydrogen atom or an optionally substituted alkyl group, and

n is an integer of 4 to 6,

or a salt thereof.

16. The method of claim 13 , wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, brain tumor, stomach cancer, and liver cancer.

Assignments (2)
CHANGE OF ADDRESS Recorded May 15, 2020
From: KNC LABORATORIES CO., LTD.
To: KNC LABORATORIES CO., LTD.
Reel/Frame 052677/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2015
From: KANAI, YOSHIKATSU; NAGAMORI, SHUSHI; KITAURA, YOSHIHIKO; NEYA, MASAHIRO; MATSUSHITA, NAOHIRO
To: OSAKA UNIVERSITY; KNC LABORATORIES CO., LTD.
Reel/Frame 036569/0340 →
Priority Claims (1)
JP 2013-008785 · Jan 21, 2013 · national
Continuity (1)
Related Publication 20150336876A1 · Nov 26, 2015